Xintela AB (publ) (STO:XINT)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.247
-0.018 (-6.79%)
Apr 28, 2026, 5:29 PM CET
-41.19%
Market Cap 212.73M
Revenue (ttm) 2.28M
Net Income (ttm) -48.56M
Shares Out 861.27M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 542,473
Average Volume 340,875
Open 0.260
Previous Close 0.265
Day's Range 0.240 - 0.260
52-Week Range 0.210 - 0.534
Beta 2.14
RSI 48.55
Earnings Date May 22, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 13
Stock Exchange Nasdaq Stockholm
Ticker Symbol XINT
Full Company Profile

Financial Performance

In 2025, Xintela AB's revenue was 2.28 million, a decrease of -45.86% compared to the previous year's 4.22 million. Losses were -48.56 million, 23.9% more than in 2024.

Financial Statements

News

There is no news available yet.